APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney Cancer Targeted Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Kidney Cancer Targeted Therapy Market Outlook and Growth Opportunities 2026

30 December 2025198 pages

Choose your research edition.

Industry ResearchKidney Cancer Targeted Therapy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney Cancer Targeted Therapy Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Kidney Cancer Targeted Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney Cancer Targeted Therapy Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney Cancer Targeted Therapy Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Kidney Cancer Targeted Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Kidney Cancer Targeted Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Kidney Cancer Targeted Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Kidney Cancer Targeted Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Kidney Cancer Targeted Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Kidney Cancer Targeted Therapy market include Aveo Pharmaceuticals, Exelixis, Wyeth, Amgen, Bayer, Pfizer, Roche, Merck and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Kidney Cancer Targeted Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Kidney Cancer Targeted Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Kidney Cancer Targeted Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Kidney Cancer Targeted Therapy market.

Kidney Cancer Targeted Therapy Segment by Company

Aveo Pharmaceuticals

Exelixis

Wyeth

Amgen

Bayer

Pfizer

Roche

Merck

Novartis

Eisai

Kidney Cancer Targeted Therapy Segment by Type

Tyrosine Kinase Inhibitors

Anti-VEGF Monoclonal Antibody

mTOR Inhibitors

EGFR Inhibitors

Kidney Cancer Targeted Therapy Segment by Application

Renal Cell Cancer

Renal Pelvis Cancer

Others

Kidney Cancer Targeted Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Kidney Cancer Targeted Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Kidney Cancer Targeted Therapy key companies, revenue, market share, and recent developments.

3. To split the Kidney Cancer Targeted Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Kidney Cancer Targeted Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Kidney Cancer Targeted Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Kidney Cancer Targeted Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer Targeted Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer Targeted Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer Targeted Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Kidney Cancer Targeted Therapy industry.

Chapter 3: Detailed analysis of Kidney Cancer Targeted Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Kidney Cancer Targeted Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Kidney Cancer Targeted Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Kidney Cancer Targeted Therapy Industry Trends Table 2. Kidney Cancer Targeted Therapy Industry Drivers Table 3. Kidney Cancer Targeted Therapy Industry Opportunities and Challenges Table 4. Kidney Cancer Targeted Therapy Industry Restraints Table 5. Global Kidney Cancer Targeted Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Kidney Cancer Targeted Therapy Revenue Share by Company (2021-2026) Table 7. Global Kidney Cancer Targeted Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Kidney Cancer Targeted Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Kidney Cancer Targeted Therapy Company, Product Type & Application Table 10. Global Kidney Cancer Targeted Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Kidney Cancer Targeted Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tyrosine Kinase Inhibitors Table 15. Significant Companies of Anti-VEGF Monoclonal Antibody Table 16. Significant Companies of mTOR Inhibitors Table 17. Significant Companies of EGFR Inhibitors Table 18. Global Kidney Cancer Targeted Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Kidney Cancer Targeted Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Kidney Cancer Targeted Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Kidney Cancer Targeted Therapy Sales Value Share by Type (2021-2026) Table 22. Global Kidney Cancer Targeted Therapy Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Renal Cell Cancer Table 24. Significant Companies of Renal Pelvis Cancer Table 25. Significant Companies of Others Table 26. Global Kidney Cancer Targeted Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Kidney Cancer Targeted Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Kidney Cancer Targeted Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Kidney Cancer Targeted Therapy Sales Value Share by Application (2021-2026) Table 30. Global Kidney Cancer Targeted Therapy Sales Value Share by Application (2027-2032) Table 31. Global Kidney Cancer Targeted Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Kidney Cancer Targeted Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Kidney Cancer Targeted Therapy Sales Value Share by Region (2021-2026) Table 34. Global Kidney Cancer Targeted Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Kidney Cancer Targeted Therapy Sales Value Share by Region (2027-2032) Table 36. Global Kidney Cancer Targeted Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Kidney Cancer Targeted Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Kidney Cancer Targeted Therapy Sales Value Market Share by Country (2021-2026) Table 39. Global Kidney Cancer Targeted Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Kidney Cancer Targeted Therapy Sales Value Market Share by Country (2027-2032) Table 41. Aveo Pharmaceuticals Company Information Table 42. Aveo Pharmaceuticals Business Overview Table 43. Aveo Pharmaceuticals Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Aveo Pharmaceuticals Kidney Cancer Targeted Therapy Product Portfolio Table 45. Aveo Pharmaceuticals Recent Development Table 46. Exelixis Company Information Table 47. Exelixis Business Overview Table 48. Exelixis Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Exelixis Kidney Cancer Targeted Therapy Product Portfolio Table 50. Exelixis Recent Development Table 51. Wyeth Company Information Table 52. Wyeth Business Overview Table 53. Wyeth Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Wyeth Kidney Cancer Targeted Therapy Product Portfolio Table 55. Wyeth Recent Development Table 56. Amgen Company Information Table 57. Amgen Business Overview Table 58. Amgen Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Amgen Kidney Cancer Targeted Therapy Product Portfolio Table 60. Amgen Recent Development Table 61. Bayer Company Information Table 62. Bayer Business Overview Table 63. Bayer Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Bayer Kidney Cancer Targeted Therapy Product Portfolio Table 65. Bayer Recent Development Table 66. Pfizer Company Information Table 67. Pfizer Business Overview Table 68. Pfizer Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Pfizer Kidney Cancer Targeted Therapy Product Portfolio Table 70. Pfizer Recent Development Table 71. Roche Company Information Table 72. Roche Business Overview Table 73. Roche Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Roche Kidney Cancer Targeted Therapy Product Portfolio Table 75. Roche Recent Development Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Merck Kidney Cancer Targeted Therapy Product Portfolio Table 80. Merck Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Novartis Kidney Cancer Targeted Therapy Product Portfolio Table 85. Novartis Recent Development Table 86. Eisai Company Information Table 87. Eisai Business Overview Table 88. Eisai Kidney Cancer Targeted Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Eisai Kidney Cancer Targeted Therapy Product Portfolio Table 90. Eisai Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Kidney Cancer Targeted Therapy Product Image Figure 2. Global Kidney Cancer Targeted Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney Cancer Targeted Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Kidney Cancer Targeted Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tyrosine Kinase Inhibitors Image Figure 8. Anti-VEGF Monoclonal Antibody Image Figure 9. mTOR Inhibitors Image Figure 10. EGFR Inhibitors Image Figure 11. Global Kidney Cancer Targeted Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Kidney Cancer Targeted Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Kidney Cancer Targeted Therapy Sales Value Share by Type (2021-2032) Figure 14. Renal Cell Cancer Image Figure 15. Renal Pelvis Cancer Image Figure 16. Others Image Figure 17. Global Kidney Cancer Targeted Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Kidney Cancer Targeted Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Kidney Cancer Targeted Therapy Sales Value Share by Application (2021-2032) Figure 20. Global Kidney Cancer Targeted Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Kidney Cancer Targeted Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Kidney Cancer Targeted Therapy Sales Value (2021-2032) & (US$ Million) Figure 23. North America Kidney Cancer Targeted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Kidney Cancer Targeted Therapy Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Kidney Cancer Targeted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Kidney Cancer Targeted Therapy Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Kidney Cancer Targeted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Kidney Cancer Targeted Therapy Sales Value (2021-2032) & (US$ Million) Figure 29. South America Kidney Cancer Targeted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Kidney Cancer Targeted Therapy Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Kidney Cancer Targeted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Tyrosine Kinase Inhibitors
  • Anti-VEGF Monoclonal Antibody
  • mTOR Inhibitors
  • EGFR Inhibitors
Applications
  • Renal Cell Cancer
  • Renal Pelvis Cancer
  • Others
Companies covered
  • Aveo Pharmaceuticals
  • Exelixis
  • Wyeth
  • Amgen
  • Bayer
  • Pfizer
  • Roche
  • Merck
  • Novartis
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Kidney Cancer Targeted Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Kidney Cancer Targeted Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Kidney Cancer Targeted Therapy Market Dynamics
  1. 2.1 Kidney Cancer Targeted Therapy Industry Trends
  2. 2.2 Kidney Cancer Targeted Therapy Industry Drivers
  3. 2.3 Kidney Cancer Targeted Therapy Industry Opportunities and Challenges
  4. 2.4 Kidney Cancer Targeted Therapy Industry Restraints
3 Kidney Cancer Targeted Therapy Market by Company
  1. 3.1 Global Kidney Cancer Targeted Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Kidney Cancer Targeted Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Kidney Cancer Targeted Therapy Company Ranking (2024-2026)
  4. 3.4 Global Kidney Cancer Targeted Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Kidney Cancer Targeted Therapy Company Product Type and Application
  6. 3.6 Global Kidney Cancer Targeted Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Kidney Cancer Targeted Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Kidney Cancer Targeted Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Kidney Cancer Targeted Therapy Market by Type
  1. 4.1 Kidney Cancer Targeted Therapy Type Introduction
  2. 4.1.1 Tyrosine Kinase Inhibitors
  3. 4.1.2 Anti-VEGF Monoclonal Antibody
  4. 4.1.3 mTOR Inhibitors
  5. 4.1.4 EGFR Inhibitors
  6. 4.2 Global Kidney Cancer Targeted Therapy Sales Value by Type
  7. 4.2.1 Global Kidney Cancer Targeted Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Kidney Cancer Targeted Therapy Sales Value by Type (2021-2032)
  9. 4.2.3 Global Kidney Cancer Targeted Therapy Sales Value Share by Type (2021-2032)
5 Kidney Cancer Targeted Therapy Market by Application
  1. 5.1 Kidney Cancer Targeted Therapy Application Introduction
  2. 5.1.1 Renal Cell Cancer
  3. 5.1.2 Renal Pelvis Cancer
  4. 5.1.3 Others
  5. 5.2 Global Kidney Cancer Targeted Therapy Sales Value by Application
  6. 5.2.1 Global Kidney Cancer Targeted Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Kidney Cancer Targeted Therapy Sales Value by Application (2021-2032)
  8. 5.2.3 Global Kidney Cancer Targeted Therapy Sales Value Share by Application (2021-2032)
6 Kidney Cancer Targeted Therapy Regional Value Analysis
  1. 6.1 Global Kidney Cancer Targeted Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Kidney Cancer Targeted Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Kidney Cancer Targeted Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Kidney Cancer Targeted Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Kidney Cancer Targeted Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Kidney Cancer Targeted Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Kidney Cancer Targeted Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Kidney Cancer Targeted Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Kidney Cancer Targeted Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Kidney Cancer Targeted Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Kidney Cancer Targeted Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Kidney Cancer Targeted Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Kidney Cancer Targeted Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Kidney Cancer Targeted Therapy Sales Value Share by Country, 2025 VS 2032
7 Kidney Cancer Targeted Therapy Country-level Value Analysis
  1. 7.1 Global Kidney Cancer Targeted Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Kidney Cancer Targeted Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Kidney Cancer Targeted Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Kidney Cancer Targeted Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Kidney Cancer Targeted Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Kidney Cancer Targeted Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Kidney Cancer Targeted Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aveo Pharmaceuticals
  2. 8.1.1 Aveo Pharmaceuticals Company Information
  3. 8.1.2 Aveo Pharmaceuticals Business Overview
  4. 8.1.3 Aveo Pharmaceuticals Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aveo Pharmaceuticals Kidney Cancer Targeted Therapy Product Portfolio
  6. 8.1.5 Aveo Pharmaceuticals Recent Developments
  7. 8.2 Exelixis
  8. 8.2.1 Exelixis Company Information
  9. 8.2.2 Exelixis Business Overview
  10. 8.2.3 Exelixis Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Exelixis Kidney Cancer Targeted Therapy Product Portfolio
  12. 8.2.5 Exelixis Recent Developments
  13. 8.3 Wyeth
  14. 8.3.1 Wyeth Company Information
  15. 8.3.2 Wyeth Business Overview
  16. 8.3.3 Wyeth Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Wyeth Kidney Cancer Targeted Therapy Product Portfolio
  18. 8.3.5 Wyeth Recent Developments
  19. 8.4 Amgen
  20. 8.4.1 Amgen Company Information
  21. 8.4.2 Amgen Business Overview
  22. 8.4.3 Amgen Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Kidney Cancer Targeted Therapy Product Portfolio
  24. 8.4.5 Amgen Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Kidney Cancer Targeted Therapy Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Kidney Cancer Targeted Therapy Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Kidney Cancer Targeted Therapy Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Merck
  44. 8.8.1 Merck Company Information
  45. 8.8.2 Merck Business Overview
  46. 8.8.3 Merck Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck Kidney Cancer Targeted Therapy Product Portfolio
  48. 8.8.5 Merck Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Kidney Cancer Targeted Therapy Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Eisai
  56. 8.10.1 Eisai Company Information
  57. 8.10.2 Eisai Business Overview
  58. 8.10.3 Eisai Kidney Cancer Targeted Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eisai Kidney Cancer Targeted Therapy Product Portfolio
  60. 8.10.5 Eisai Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst